Drug Profile
Research programme: CAR-T cell therapies - Eutilex
Alternative Names: CAR-T cell therapy - Eutilex; MVR CAR-T; Solid cancer specialized CAR-TLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Eutilex
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for research development in Cancer in South Korea (Parenteral)
- 07 Apr 2020 GenScript ProBio collaborates with Eutilex for plasmid and virus process development and manufacturing for CAR-T programs
- 17 Apr 2018 Pharmacodynamics data from a study in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)